ArticleScience (New York, N.Y.)2021
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors.
Article in Science (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 202 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
202 citing papers in PubMed, 4 syntheses or guidelines pooled it, 349 citations in OpenAlex.
- Seroprevalence of SARS-CoV-2 Antibodies in Africa: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022Pooled it
- SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis.European journal of medical research · 2022Pooled it
- Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis.Reviews in medical virology · 2022Pooled it
- Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis.The Lancet. Global health · 2021Pooled it
- Neoadjuvant chemotherapy in women with triple-negative breast cancer: real world results from Western Kenya.The oncologist · 2026Article
- SARS-CoV-2 seroprevalence among pregnant women during the first three waves of the COVID-19 pandemic in southern Mozambique.BMC pregnancy and childbirth · 2026Observational
- DETECTION OF SARS-COV-2 IN MULTIPLE CLINICAL SPECIMENS: A PILOT PREVALENCE STUDY FROM NORTHEAST NIGERIA.Annals of Ibadan postgraduate medicine · 2026Article
- Determinants of long-term SARS-CoV-2 immune responses in asymptomatic-to-moderate COVID-19 patients in sub-Saharan Africa.BMC medicine · 2026Article
- Article
- Article
- Review
- Epidemiological and antigenic inferences from serological cross-reactivity among arboviruses.Science translational medicine · 2025Article
- Seroprevalence and molecular detection of SARS-CoV-2 among apparently healthy healthcare workers and patients in a Nigerian tertiary hospital.BMC infectious diseases · 2025Article
- Article
- Article
- Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Coronavirus Disease 2019 Vaccination Trends: Findings from Surveillance Conducted at First Antenatal Care Visits in Kenya, Nigeria, Malawi, Mozambique, Uganda, and Zambia, 2021-2022.The American journal of tropical medicine and hygiene · 2025Article
- Article
- Rethinking the evidence on COVID-19 in Africa.The Lancet. Infectious diseases · 2025Review
- Comparison of Infection-Induced SARS-CoV-2 Seroprevalence Across Large-Scale Residual Samples From Blood Donors, Commercial Laboratories, and Health Checkups in Japan, 2023.Open forum infectious diseases · 2025Article
- Article
142 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
39 authors at 6 institutions in 2 countries.
Funding
Abstract
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Africa is poorly described. The first case of SARS-CoV-2 in Kenya was reported on 12 March 2020, and an overwhelming number of cases and deaths were expected, but by 31 July 2020, there were only 20,636 cases and 341 deaths. However, the extent of SARS-CoV-2 exposure in the community remains unknown. We determined the prevalence of anti-SARS-CoV-2 immunoglobulin G among blood donors in Kenya in April-June 2020. Crude seroprevalence was 5.6% (174 of 3098). Population-weighted, test-performance-adjusted national seroprevalence was 4.3% (95% confidence interval, 2.9 to 5.8%) and was highest in urban counties Mombasa (8.0%), Nairobi (7.3%), and Kisumu (5.5%). SARS-CoV-2 exposure is more extensive than indicated by case-based surveillance, and these results will help guide the pandemic response in Kenya and across Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.